Literature DB >> 8227738

Coagulation disorders in septic shock.

L G Thijs1, J P de Boer, M C de Groot, C E Hack.   

Abstract

Abnormalities in coagulation and fibrinolysis are frequently observed in septic shock. The most pronounced clinical manifestation is disseminated intravascular coagulation. Recent studies in human volunteers and animal models have clarified the early dynamics and route of activation of both coagulation and fibrinolytic pathways. In healthy subjects subjected to a low dose of either endotoxin or TNF an imbalance in the procoagulant and the fibrinolytic mechanisms is apparent, resulting in a procoagulant state. Also in patients with septic shock a dynamic process of coagulation and fibrinolysis is ongoing with evidence of impaired fibrinolysis. These abnormalities have prognostic significance; the extent of disturbances of coagulation and fibrinolysis is related to the development of multiple organ failure and death.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227738     DOI: 10.1007/bf01738944

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  64 in total

1.  Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.

Authors:  P Brandtzaeg; G B Joø; B Brusletto; P Kierulf
Journal:  Thromb Res       Date:  1990-01-15       Impact factor: 3.944

2.  Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.

Authors:  F B Taylor; T E Emerson; R Jordan; A K Chang; K E Blick
Journal:  Circ Shock       Date:  1988-11

3.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

Authors:  F B Taylor; A Chang; C T Esmon; A D'Angelo; S Vigano-D'Angelo; K E Blick
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

4.  Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator.

Authors:  J Wojta; R L Hoover; T O Daniel
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

5.  Cultured human endothelial cells generate tissue factor in response to endotoxin.

Authors:  M Colucci; G Balconi; R Lorenzet; A Pietra; D Locati; M B Donati; N Semeraro
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

6.  Thrombin induction of plasminogen activator inhibitor mRNA in human umbilical vein endothelial cells in culture.

Authors:  J H Heaton; M K Dame; T D Gelehrter
Journal:  J Lab Clin Med       Date:  1992-08

7.  Cytokine appearance in human endotoxemia and primate bacteremia.

Authors:  D G Hesse; K J Tracey; Y Fong; K R Manogue; M A Palladino; A Cerami; G T Shires; S F Lowry
Journal:  Surg Gynecol Obstet       Date:  1988-02

8.  Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents.

Authors:  G D Martich; R L Danner; M Ceska; A F Suffredini
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

9.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; R S Cotran; M A Gimbrone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

10.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  9 in total

1.  Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation.

Authors:  Seiji Madoiwa; Shin Nunomiya; Tomoko Ono; Yuichi Shintani; Tsukasa Ohmori; Jun Mimuro; Yoichi Sakata
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

2.  Serum MIP-1 alpha and IL-8 in septic patients.

Authors:  S Fujishima; J Sasaki; Y Shinozawa; K Takuma; H Kimura; M Suzuki; M Kanazawa; S Hori; N Aikawa
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

3.  Underlying Disorders, Clinical Phenotypes, and Treatment Diversity among Patients with Disseminated Intravascular Coagulation.

Authors:  Hiroyuki Ohbe; Kazuma Yamakawa; Kohei Taniguchi; Kojiro Morita; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga
Journal:  JMA J       Date:  2020-09-23

Review 4.  Blood-brain barrier breakdown in septic encephalopathy and brain tumours.

Authors:  D C Davies
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

5.  Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?

Authors:  B Leithäuser; F R Matthias; U Nicolai; R Voss
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

6.  Ozone therapy in induced endotoxemic shock. II. The effect of ozone therapy upon selected histochemical reactions in organs of rats in endotoxemic shock.

Authors:  Paweł Madej; Andrzej Plewka; Janusz A Madej; Danuta Plewka; Wojciech Mroczka; Krzysztof Wilk; Zuzanna Dobrosz
Journal:  Inflammation       Date:  2007-04-26       Impact factor: 4.092

7.  Advances in Sepsis Treatment.

Authors:  Todd W Rice; Gordon R Bernard
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

Review 8.  Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.

Authors:  Todd W Rice
Journal:  Vasc Health Risk Manag       Date:  2006

9.  The imbalance between coagulation and fibrinolysis is related to the severity of the illness and the prognosis in sepsis.

Authors:  K J Park; H J Kim; S C Hwang; S M Lee; Y H Lee; M H Hahn; S K Kim; W Y Lee
Journal:  Korean J Intern Med       Date:  1999-07       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.